| Intravital Microscopy in Human Solid Tumors (NCT03823144) | Mayo Clinic | 2019-02-28 |
| First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer (NCT03873883) | iTeos Therapeutics | 2019-02-05 |
| RACIN in Patients With Advanced TIL-negative Solid Tumors (NCT03728179) | Centre Hospitalier Universitaire Vaudois | 2019-01-16 |
| Psychotherapy Intervention for Latinos With Adv Cancer (NCT04537936) | Memorial Sloan Kettering Cancer Center | 2019-01-01 |
| MGD019 DART® Protein in Unresectable/Metastatic Cancer (NCT03761017) | MacroGenics | 2018-12-12 |
| Cannabis Use in Cancer Patients (NCT03617692) | University of Colorado, Denver | 2018-12-04 |
| Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies (NCT03772561) | National University Hospital, Singapore | 2018-12-03 |
| TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors (NCT03778814) | Second Affiliated Hospital of Guangzhou Medical University | 2018-12-01 |
| 89Zr-KN035 PET Imaging in Patients With Advanced Solid Tumors (NCT03638804) | The First Affiliated Hospital of Soochow University | 2018-11-12 |
| Study of PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning of PC in Mesothelin Positive Multiple Solid Tumors (NCT03747965) | Chinese PLA General Hospital | 2018-11-01 |
| Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer (NCT03600090) | Taizhou EOC Pharma Co., Ltd. | 2018-10-16 |
| Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors (NCT03496519) | University of Colorado, Denver | 2018-10-01 |
| Advanced Refractory Solid Tumors With TP53 Mutations Register Study (NCT03927599) | Tianjin Medical University Second Hospital | 2018-08-01 |
| A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS (NCT03573310) | Janssen Research & Development, LLC | 2018-07-13 |
| A Study of HQP1351 in Patients With GIST or Other Solid Tumors (NCT03594422) | Ascentage Pharma Group Inc. | 2018-07-11 |
| PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL (NCT03543813) | CytomX Therapeutics | 2018-06-15 |
| A Study of CS3006 in Subjects with Locally Advanced or Metastatic Solid Tumors (NCT03516123) | CStone Pharmaceuticals | 2018-06-14 |
| Study of ASTX029 in Subjects With Advanced Solid Tumors (NCT03520075) | Taiho Oncology, Inc. | 2018-05-07 |
| A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (NCT03475953) | Institut Bergonié | 2018-05-04 |
| Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma (NCT03465592) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2018-05-01 |
| A Study of CS1002 in Subjects with Advanced Solid Tumors (NCT03523819) | CStone Pharmaceuticals | 2018-04-26 |
| A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors (NCT03494231) | Henlix, Inc | 2018-03-22 |
| Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors. (NCT03545815) | Chinese PLA General Hospital | 2018-03-19 |
| Comparison of Humeral or Thoracic Implantation of an Central Veinous Access by an Implantable Venous Access Device in Patients With Solid Tumors Requiring Chemotherapy (NCT03410121) | Center Eugene Marquis | 2018-03-09 |
| IMX-110 in Patients With Advanced Solid Tumors (NCT03382340) | Immix Biopharma Australia Pty Ltd | 2018-02-15 |
| Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors (NCT03398720) | Jiangsu HengRui Medicine Co., Ltd. | 2017-12-31 |
| K-BASKET, TAS-117, PI3K/AKT Gene Aberration (NCT03017521) | Yonsei University | 2017-11-21 |
| A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors (NCT03355066) | Biosplice Therapeutics, Inc. | 2017-11-06 |
| Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors (NCT03274661) | Baptist Health South Florida | 2017-11-03 |
| Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies (NCT03209401) | Georgetown University | 2017-10-13 |
| Circulating Tumor DNA As Liquid Biopsy in Patients with Stage IV Solid Tumors, a Feasibility Study At MUSC HCC (NCT03302325) | Medical University of South Carolina | 2017-10-12 |
| Absorption and Excretion of Oral Docetaxel (NCT05242926) | Modra Pharmaceuticals | 2017-10-01 |
| Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours (NCT03008018) | Karus Therapeutics Limited | 2017-08-07 |
| Telatinib Safety and Pharmacokinetics Study in China Patients With Advanced Solid Tumors (NCT03175497) | Taizhou EOC Pharma Co., Ltd. | 2017-07-25 |
| POA Prospective Repository (NCT03324841) | Caris Science, Inc. | 2017-06-07 |
| PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors (NCT03149549) | CytomX Therapeutics | 2017-06-01 |
| Personalized Therapy of Molecular Tumor Board Participation With the Guidance of Next Generation Sequencing (NCT03929653) | Tianjin Medical University Second Hospital | 2017-06-01 |
| A Study of AK-01 (LY3295668) in Solid Tumors (NCT03092934) | Eli Lilly and Company | 2017-05-29 |
| SHIVA02 - Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control (SHIVA02) (NCT03084757) | Institut Curie | 2017-05-26 |
| A Study of HMPL-453 in Patients With Advanced Solid Malignancies (NCT03160833) | Hutchison Medipharma Limited | 2017-05-23 |
| Food Effect Study of ModraDoc006 in Combination With Ritonavir (NCT03147378) | Modra Pharmaceuticals | 2017-05-10 |
| Interest of Reticulocyte Haemoglobin Content (RET-he) in Management of Functional Anemia for Patient With Solid Tumor (NCT03656172) | Institut Cancerologie de l'Ouest | 2017-05-04 |
| A Phase I Study of SH003 for Evaluate Safe Dose Range in Patients With Solid Cancer (NCT03081819) | Kyunghee University Medical Center | 2017-03-29 |
| AVID100 in Advanced Epithelial Carcinomas (NCT03094169) | Formation Biologics | 2017-02-01 |
| A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) (NCT02974738) | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2016-12-07 |
| POA Retrospective Repository (NCT03326479) | Caris Science, Inc. | 2016-11-30 |
| A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours (NCT02977364) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2016-11-01 |
| 18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR (NCT02717572) | Washington University School of Medicine | 2016-03-01 |
| Perfusion-Induced Hyperthermia for Metastatic Carcinoma (NCT02409108) | Jonathan Kiev | 2015-07-01 |
| Psychotherapy Intervention for Latinos With Advanced Cancer (NCT04015609) | Memorial Sloan Kettering Cancer Center | 2015-04-20 |
| The PEACE (Posthumous Evaluation of Advanced Cancer Environment) Study (NCT03004755) | University College, London | 2014-03-01 |
| Testing Two Different Intensities of an Intervention to Enhance REsilience and to Reduce SupportIve Care Needs in Cancer Patients (NCT03045003) | Manuela Eicher | 2014-01-01 |
| Circulating Tumor Cells in Solid Tumors (NCT03161821) | UNC Lineberger Comprehensive Cancer Center | 2011-12-09 |
| Evaluation of Different Analysis Methods for Circulating Tumor Cells, Circulating Endothelial Cell, and Circulating Tumor DNA in Patient Followed for a Tumoral Pathology (NCT02220556) | Institut Curie | 2010-12-01 |
| A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells. (NCT00571389) | BioCytics, Inc. | 2007-11-01 |
| Expanded Access Neoantigen Vaccine in Solid Tumors (NCT03914872) | Washington University School of Medicine | |
| MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer (NCT06980506) | Monopar Therapeutics | |